RNA Outsourcing Videos

31. No Cells, No Limits To DNA Production: Inside Synthetic DNA 6/12/2025

    Here, we walk you through our groundbreaking, enzymatic DNA manufacturing process that enables the production of linear DNA templates for IVT mRNA synthesis — without the use of cells.

32. Customized mRNA Processing For Improved Therapy Development And Manufacturing 2/13/2025

    Optimize mRNA development by learning key strategies for process refinement, critical component identification, and in-process analytics to enhance therapeutic production.

33. Regulatory Confidence, Manufacturing Excellence 10/20/2025

    With decades of experience, we offer a flexible and collaborative partnership model for manufacturing excellence that enables our clients to increase speed to market with full regulatory confidence.

34. ReciBioPharm Capacity Update July 2025: Analytical Services 7/28/2025

    ReciBioPharm’s specialized CDMO capabilities include development and manufacture for new biological modalities. Discover the benefits of choosing a CDMO with complete end-to-end services and in-house analytical capabilities.

35. Scale-Up And Production Of Key Lipids Used In mRNA Delivery Systems 2/13/2025

    Discover key strategies for overcoming challenges in the industrial-scale production of ionizable and PEG lipids to optimize mRNA vaccine formulation and address critical manufacturing requirements.

36. Innovative RNA Manufacturing: Breaking Barriers With Mutant T7 Polymerase 2/11/2025

    Discover how advanced mRNA manufacturing innovations, including optimized RNA synthesis and scalable LNP encapsulation, are accelerating therapeutic development.

37. Mitigating Financial Risk Before Selecting An Outsourcing Vendor 9/25/2023

    Gain insight from several clinical operations experts into the significance of meticulous contract examination when choosing an outsourcing partner.

38. mRNA Capabilities 3/4/2025

    Discover how our advanced capabilities in Hopkinton, MA, are overcoming the challenges of large-scale RNA therapeutic manufacturing, enabling the efficient production of complex srRNA and mRNA therapies.

39. Face- Phase-Off: Matching CDMO Capabilities To Your mRNA-LNP Development Stage 2/10/2025

    There are many different criteria for selecting a CDMO for your mRNA products. Arcturus’ Qian Ruan explains that a product’s stage of development and the specific needs inherent to that phase of development should be an important guide for companies today, especially given the expansion of the outsourcing sector and the wide range of capabilities.

40. How Are The Costs Of mRNA-LNP Manufacturing Evolving? 2/10/2025

    Achieving cost-effective manufacturing while maintaining high quality standards today is one of the biggest challenges facing companies outsourcing mRNA/RNA development. In turn, panelists Qian Ruan, Andy Geall, and Alex Aust reflect on how and where they’ve seen the costs of mRNA-LNP manufacturing evolving/fluctuating in recent years.